Sign inJoin waitlistJoin the waitlist

AG

Andrew Gianoukakis

Program Director · University of Southern California/Los Angeles General Medical Center

Credentials: · · · ·

History

Endocrinology, Diabetes, and Metabolism
Albany Med Health System
1997–1999
Internal Medicine
1993–1996
UNIV OF PATRAS, PATRAS
1989–1993

Research

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
New England Journal of Medicine · 2015 · 1,570 citations
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease
The Journal of Immunology · 2008 · 299 citations
Increased generation of fibrocytes in thyroid-associated ophthalmopathy
The Journal of Clinical Endocrinology & Metabolism · 2010 · 173 citations

TS
Terry Smith
15 papers
RD
Raymond Douglas
8 papers
LW
Lori Wirth
7 papers
LM
Laron McPhaul
5 papers
Marcia Brose
5 papers
Matthew Taylor
5 papers
Bhavana Konda
4 papers
Steven Sherman
4 papers
Catherine Hwang
3 papers · 3 as a fellow
FW
Francis Worden
3 papers
MY
Marelle Yehuda
3 papers · 2 as a fellow
PM
Paul Madaj
3 papers · 3 as a resident

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $797.8K · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
2003–2010
Thyrocytes Express Inflammatory Mediators
National Center for Research Resources · K23
Contact PI · $669.4K · Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center
2002–2008

Clinical trials

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Site PI · Recruiting · Phase 2
Jochen Lorch
2025–2030
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Site PI · Recruiting
Novartis Pharmaceuticals
2024–2028